Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
2023 · Nature Communications · 33 citations
https://doi.org/10.1038/s41467-023-40758-0
J
Jonas Rieth
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
25
Papers
1.4K
Citations
10
h-index
10
i10-index
Jonas Rieth is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: COVID-19 Clinical Research Studies & SARS-CoV-2 and COVID-19 Research & Immunotherapy and Immune Responses. The author has an h-index of 10, co-authored 22 publications.
Papers by this author
worksExtracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics
2017 · International Immunopharmacology · 17 citations
https://doi.org/10.1016/j.intimp.2017.10.021
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity
2022 · iScience · 11 citations
https://doi.org/10.1016/j.isci.2022.105643
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat